Meeting
2018 ASCO Annual Meeting
Phase I-b study of isatuximab + carfilzomib in relapsed and refractory multiple myeloma (RRMM).
Authors
Ajai Chari
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
Ajai Chari , Joshua Ryan Richter , Nina Shah , Sandy Wai Kuan Wong , Sundar Jagannath , Hearn J. Cho , Noa Biran , Jeffrey Wolf , Samir S. Parekh , Pamela N. Munster , Deepu Madduri , Frank Campana , Thomas G. Martin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies—Plasma Cell Dyscrasia
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT-02332850
Citation
J Clin Oncol 36, 2018 (suppl; abstr 8014)
DOI
10.1200/JCO.2018.36.15_suppl.8014
Abstract #
8014
Poster Bd #
23
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Updated results from CHAMPION-1, a phase I/II study investigating weekly carfilzomib with dexamethasone for patients (Pts) with relapsed or refractory multiple myeloma (RRMM).
First Author: James R. Berenson
Poster
2018 ASCO Annual Meeting
Weekly carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed or refractory multiple myeloma (RRMM): A phase 1b study.
First Author: Noa Biran
Poster
2018 ASCO Annual Meeting
A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
First Author: Andrew Jenho Yee
Poster
2014 ASCO Annual Meeting
A phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone (QUAD) in relapsed and/or refractory multiple myeloma (MM).
First Author: David H. Vesole